强生公司旗下药物Tremfya在治疗中取得积极进展,据格隆汇10月7日消息,该药物在治疗过程中,于第48周实现了36.7%的临床缓解率,这一数据体现了Tremfya在相应病症治疗中的一定效果,显示出其在改善患者病情方面具有积极作用,为相关病症的治疗提供了新的选择和希望,不过目前关于该药物更详细的治疗效果、适用范围以及长期影响等方面的信息尚未完全披露,后续还需进一步关注其在临床应用中的表现以及更多...
Source Link强生公司旗下药物Tremfya在治疗中取得积极进展,据格隆汇10月7日消息,该药物在治疗过程中,于第48周实现了36.7%的临床缓解率,这一数据体现了Tremfya在相应病症治疗中的一定效果,显示出其在改善患者病情方面具有积极作用,为相关病症的治疗提供了新的选择和希望,不过目前关于该药物更详细的治疗效果、适用范围以及长期影响等方面的信息尚未完全披露,后续还需进一步关注其在临床应用中的表现以及更多...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.